Figure 1From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer Kaplan-Meier curves for (A) overall survival (OS) and (B) progression free survival (PFS) for patients with EGFR-positive ( n = 152) and EGFR-negative ( n = 205) disease. Median OS: 10.9 vs 10.6 months, p = 0.463; median PFS: 5.3 vs 5.7 months, p = 0.185.Back to article page